CHANDAN HEALTHCARE LIMITED
Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021
CIN: L85110UP2003PLC193493
TELNO.: -8069366666 **Email:** secretarial@chandan.co.in
www.chandandiagnostic.com

Date: August 14, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN
ISIN: INE0B2N01016

Ref: Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub Outcome of Board Meeting held on Friday, August 14, 2026

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force, we wish to inform you that the Board of Directors of Chandan Healthcare Limited ("the Company"), at its meeting held today, i.e., **Friday, August 14, 2026**, has, inter alia, considered and approved/taken on record the following:

(a) Considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, pursuant to Regulation 33 of the SEBI Listing Regulations;

(b) Taken on record the Limited Review Reports issued by the Statutory Auditors of the Company on the aforesaid Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026;

(c) Taken on record the certificate issued by the Statutory Auditors of the Company regarding utilization of IPO funds; and

(d) Taken on record the certificate issued by the Statutory Auditors of the Company regarding utilization of funds raised through the Preferential Issue of Share Warrants.

The aforesaid Unaudited Financial Results (Standalone and Consolidated), along with the Limited Review Reports of the Statutory Auditors, are enclosed herewith.

Further, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, **the trading window for dealing in the securities of the Company, which has been closed for the Designated Persons and their immediate relatives with effect from July 01, 2026, shall reopen after the expiry of 48 hours from the declaration of the aforesaid Unaudited Financial Results for the quarter ended June 30, 2026.**

The Board Meeting commenced at 04:00 P.M. (IST) and concluded at 06:45 P.M. (IST).

The above information is also being made available on the website of the Company at www.chandandiagnostic.com.

Kindly take the above information on record.

Thanking you,

Yours sincerely,
For Chandan Healthcare Limited

RAJEEV NAIN
Digitally signed by RAJEEV NAIN
Date: 2026.08.14 18:50:13 +05'30'

Rajeev Kumar Nain
Company Secretary & Compliance Officer

Encl.: as above

Independent Auditor's Report on Quarterly Reviewed Standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Chandan Healthcare Limited,
Lucknow

Report on the review of the Standalone Financial Results

Opinion

We have reviewed the accompanying statement of quarter to date standalone financial results of M/***s. Chandan Healthcare Limited*** (the "Company") for the quarter ended June 30, 2026 (the "Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

I. Is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

II. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit after tax and other comprehensive profit and other financial information for the quarter ended June 30, 2026,

Basis for Opinion
We conducted our review in accordance with the Standard on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibility under those Standards is further described in the Auditor's Responsibility for the review of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our review of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement have been prepared on the basis of the standalone financial statements. The Company's Board of Directors are responsible for the preparation of the Statement that give a true and fair view of the net profit and other comprehensive profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the review of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an review conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of a review in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the review. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the review in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial control with reference to financial statements in place and operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required

to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

First-time Adoption of Ind AS

The Company has adopted Indian Accounting Standards (Ind AS) with effect from 1 April 2026. Accordingly, 1 April 2025 has been considered as the date of transition to Ind AS and an opening Ind AS Balance Sheet has been prepared as at that date in accordance with Ind AS 101 – First-time Adoption of Indian Accounting Standards.

These financial results for the quarter ended 30 June 2026 are the first quarterly financial statements of the Company prepared in accordance with Ind AS. The corresponding comparative information for the quarter ended 30 June 2025 has been restated/recast, wherever applicable, to comply with the requirements of Ind AS.

The transition from previous GAAP to Ind AS has resulted in adjustments primarily relating to leases, financial instruments, employee benefits, deferred tax and other applicable Ind AS requirements. The impact of such transition adjustments on the opening equity as at 1 April 2025, equity as at 31 March 2026, and the financial performance for the relevant comparative periods has been determined in accordance with Ind AS 101.

Figures for the previous periods/year have been regrouped, restated and/or reclassified whenever considered necessary to make them comparable to the current periods.

Our opinion on the statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by the Board of Directors.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322

MSNT & ASSOCIATE LLP 018542C/C400322 CHARTERED ACCOUNTANTS

Navodit Tyagi
Partner
Membership No.-533375
UDIN No: 26533375AFEAID2339
Place: Noida
Date: 14.08.2026

COMPANY NAME :- CHANDAN HEALTHCARE LIMITED
CIN :- L85110UP2003PLC193493
REGISTERED ADDRESS :- Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Standalone Statement Of Financial Results For The Quarter Ended 30th June, 2026

Particulars	Quarter Ended			Year Ended
	30th June 2026	31st March, 2026	30th June 2025	31st March, 2026
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	4,866.72	4,477.09	3,587.73	15,664.73
II. Other income	108.82	201.91	74.67	421.00
III. Total revenue(I+II)	**4,975.54**	**4,679.00**	**3,662.40**	**16,085.73**
IV. Expenses:				
Cost of material consumed	580.50	604.09	625.33	2,281.00
Purchase of stock-in-trade	149.22	136.17	122.47	568.45
Change in inventories of finished goods,work-in-progress and stock-in-trade.	(2.69)	18.05	17.67	48.65
Employee benefits expense.	1,267.24	1,269.21	852.03	4,413.31
Finance Costs	405.98	138.57	99.05	1,185.77
Depreciation and amortisation expense	417.99	303.31	291.67	1,377.58
Other expenses	1,161.82	1,453.00	810.20	3,372.87
Total expenses (IV)	**3,980.06**	**3,922.41**	**2,818.43**	**13,247.63**
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	**995.48**	**756.60**	**843.97**	**2,838.10**
VI. Exceptional items*	-	-	-	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)	**995.48**	**756.60**	**843.97**	**2,838.10**
VIII. Extraordinary items	-	-	-	-
IX. Profit(loss) before tax (VII- VIII)	**995.48**	**756.60**	**843.97**	**2,838.10**
X. Tax expense of continuing operation:-				
Current tax	271.10	203.64	218.48	780.51
Current tax-Adjustment for earlier years	-	-		30.48
Deferred tax	53.49	61.48	87.67	253.99
Tax expense(X)	**324.59**	**265.12**	**306.15**	**1,064.98**
XI. Profit(loss) for the period from continuing operations(after tax) (IX-X)	**670.89**	**491.48**	**537.82**	**1,773.12**
XII. Profit/(loss) from discontinuing operations	-	-	-	-
XIII. Tax expense of discontinuing operations	-	-	-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	**-**	**-**	**-**	**-**
XV. Share of (profit)/ loss transferred to minority interest				**-**
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	**670.89**	**491.48**	**537.82**	**1,773.12**
XVII. Other Comprehensive (loss)/income				
Items That will not be reclassified to profit or loss				
Remeasurement gains / losses on defined benefit plans	18.73	69.32	69.32	**277.29**
Tax related to items that will not be reclassified to profit or loss	4.71	17.45	17.45	**69.79**
Total Other Comprehensive (loss)/Income(XVII)	**23.44**	**86.77**	**86.77**	**347.08**
Total Comprehensive (loss)/Income(XVI+XVII)	**694.33**	**578.25**	**624.59**	**2,120.20**
XVIII. Earnings per equity share:				
(1) Basic	2.74	2.01	2.20	7.25
(2) Diluted	2.32	1.96	2.14	7.05

First-time Adoption of Ind AS

The Company has adopted **Indian Accounting Standards (Ind AS)** with effect from **1 April 2026**. Accordingly, **1 April 2025** has been considered as the date of transition to Ind AS and an opening Ind AS Balance Sheet has been prepared as at that date in accordance with **Ind AS 101 – First-time Adoption of Indian Accounting Standards**

These financial results for the **quarter ended 30 June 2026** are the first quarterly financial statements of the Company prepared in accordance with Ind AS. The corresponding comparative information for the quarter ended **30 June 2025** has been restated/recast, wherever applicable, to comply with the requirements of Ind AS.

The transition from previous GAAP to Ind AS has resulted in adjustments primarily relating to **leases, financial instruments, employee benefits, deferred tax and other applicable Ind AS requirements** The impact of such transition adjustments on the opening equity as at **1 April 2025**, equity as at **31 March 2026**, and the financial performance for the relevant comparative periods has been determined in accordance with Ind AS 101.

Following reconciliations of equity and total comprehensive income between previous GAAP and Ind AS, along with explanations of material adjustments arising from the transition.

Statement of Changes in Equity and Statement of Impact of Transition to Ind AS on Profit and Other Comprehensive Income

Year Ended 31st March 2026

Adjustment Category	Amount	Change In Profit & OCI			
		Expense	Income	OCI	Total
Equity / Retained Earnings As Per Indian GAAP as on 01/04/2025	3,844.49				
Ind AS 19_Gratuity (Defined Benefit Obligation)	-	277.29	-	277.29	**-**
Ind AS 116_Rent Building — ROU Asset & Lease Liability	-210.72	278.54	-	-	**-278.54**
Ind AS 109_Term Loans — EIR (Amortised Cost)	29.53	-	9.91	-	**9.91**
Ind AS 109_Security Deposits — Given (Assets)	-6.65	6.60	-	-	**-6.60**
Ind AS 109_Security Deposits — Received (Liabilities)	0.27	-	0.27	-	**0.27**
Ind AS 12_Deferred Tax on Above Adjustments	-47.21	208.78	-	69.79	**-138.99**
Total	**3,609.70**	**771.22**	**10.18**	**347.08**	**-413.96**

Quarter Ended 30th June 2026

Adjustment Category	Amount	Change In Profit & OCI			
		Expense	Income	OCI	Total
Equity / Retained Earnings As Per Indian GAAP as on 01/04/2025	-	-	-	-	**-**
Ind AS 19_Gratuity (Defined Benefit Obligation)		18.73	-	18.73	**-**
Ind AS 116_Rent Building — ROU Asset & Lease Liability	-	101.10	-	-	**-101.10**
Ind AS 109_Term Loans — EIR (Amortised Cost)	-	-	20.79	-	**20.79**
Ind AS 109_Security Deposits — Given (Assets)	-	1.62	-	-	**-1.62**
Ind AS 109_Security Deposits — Received (Liabilities)	-	-	0.07	-	**0.07**
Ind AS 12_Deferred Tax on Above Adjustments	-	30.03	-	4.71	**-25.32**
Total	**-**	**151.49**	**20.85**	**23.44**	**-107.19**

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322

Navodit tyagi
Partner
Membership no. :- 533375
UDIN no. :- 26533375AFEAID2339
Place :- Noida
Date :- 14th August 2026

MSNT & ASSOCIATE LLP 018542C/C400322 CHARTERED ACCOUNTS

For & on behalf of the board of directors
CHANDAN HEALTHCARE LIMITED

Amar singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 14th August 2026

Asmita singh
Managing director
Din. :- 01098055
Place :- Lucknow
Date :- 14th August 2026

Rajeev Nain
CFO & Company secretary
Place :- 14th August 2026

Independent Auditor's Report on Quarterly Reviewed Consolidated Financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Chandan Healthcare Limited,
Lucknow

Report on the audit of the Consolidated Financial Results

Opinion

We have reviewed the accompanying Statement of quarter to date Consolidated Financial Results of ***M/s. Chandan Healthcare Limited*** (hereinafter referred to as the "Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, the Statement:

a) includes the results of the following entities:

  I. Chandan Pharmacy Limited.

  II. Chandan Diagnostic Limited.

  III. Indira Diagnostic Centre & Blood Bank Limited.

  IV. Chandan Healthcare Projects Private Limited.

b) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and

c) gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated net profit after tax and other comprehensive profit and other financial information of the Group for the quarterly ended June 30, 2026.

Basis for Opinion

We conducted our review in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the review of the Consolidated Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our review of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of Statement that give a true and fair view of the net profit and other comprehensive profit and other financial information of the Group in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group entities are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the review of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an review conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of a review in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the review. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the review in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the review of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the review and significant audit findings, including any significant deficiencies in internal control that we identify during our review.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

First-time Adoption of Ind AS

The Company has adopted Indian Accounting Standards (Ind AS) with effect from 1 April 2026. Accordingly, 1 April 2025 has been considered as the date of transition to Ind AS and an opening Ind AS Balance Sheet has been prepared as at that date in accordance with Ind AS 101 – First-time Adoption of Indian Accounting Standards.

These financial results for the quarter ended 30 June 2026 are the first quarterly financial statements of the Company prepared in accordance with Ind AS. The corresponding comparative information for the quarter ended 30 June 2025 has been restated/recast, wherever applicable, to comply with the requirements of Ind AS.

The transition from previous GAAP to Ind AS has resulted in adjustments primarily relating to leases, financial instruments, employee benefits, deferred tax and other applicable Ind AS requirements. The impact of such transition adjustments on the opening equity as at 1 April 2025, equity as at 31 March 2026, and the financial performance for the relevant comparative periods has been determined in accordance with Ind AS 101.

Figures for the previous periods/year have been regrouped, restated and/or reclassified whenever considered necessary to make them comparable to the current periods.

Our opinion on the statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by the Board of Directors.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322

MSNT & ASSOCIATE LLP
018542C/C400322
CHARTERED ACCOUNTS

Navodit Tyagi
Partner
Membership No.-533375
UDIN No: 26533375LJICNF2743
Place: Noida
Date: 14.08.2026

COMPANY NAME :- CHANDAN HEALTHCARE LIMITED
CIN :- L85110UP2003PLC193493
REGISTERED ADDRESS :- Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Consolidated Statement Of Financial Results For The Quarter Ended 30th June, 2026

Particulars	Quarter Ended			Year Ended
	30th June 2026	31st March, 2026	30th June 2025	31st March, 2026
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	8,085.33	7,558.36	6,790.17	27,639.44
II. Other income	141.02	185.04	87.15	438.56
III. Total revenue(I+II)	**8,226.35**	**7,743.40**	**6,877.32**	**28,078.00**
IV. Expenses:				
Cost of material consumed	580.13	605.12	681.93	2,286.65
Purchase of stock-in-trade	2,956.17	2,815.48	2,803.89	11,359.87
Change in inventories of finished goods,work-in-progress and stock-in-trade.	(27.56)	54.17	(41.37)	(278.05)
Employee benefits expense.	1,417.28	1,431.25	1,054.21	5,003.09
Finance Costs	482.65	177.67	137.43	1,442.54
Depreciation and amortisation expense	447.07	373.54	375.31	1,493.42
Other expenses	1,202.09	1,505.19	903.85	3,546.60
Total expenses (IV)	**7,057.83**	**6,962.42**	**5,915.24**	**24,854.12**
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	**1,168.52**	**780.97**	**962.07**	**3,223.88**
VI. Exceptional items*	-	-	-	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)	**1,168.52**	**780.97**	**962.07**	**3,223.88**
VIII. Extraordinary items	-	-	-	-
IX. Profit(loss) before tax (VII- VIII)	**1,168.52**	**780.97**	**962.07**	**3,223.88**
X. Tax expense of continuing operation:-				
Current tax	329.70	227.31	249.25	903.83
Current tax-Adjustment for earlier years	-	-	-	30.48
Deferred tax	47.74	59.27	94.44	262.16
Tax expense(X)	**377.44**	**286.58**	**343.69**	**1,196.47**
XI. Profit(loss) for the period from continuing operations(after tax) (IX-X)	**791.08**	**494.39**	**618.39**	**2,027.41**
XII. Profit/(loss) from discontinuing operations	-	-	-	-
XIII. Tax expense of discontinuing operations	-	-	-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	**-**	**-**	**-**	**-**
XV. Share of (profit)/ loss transferred to minority interest	(41.58)	(3.94)	**(39.66)**	**(87.55)**
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	**749.50**	**490.45**	**578.73**	**1,939.86**
XVII. Other Comprehensive (loss)/income				
Items That will not be reclassified to profit or loss				
Remeasurement gains / losses on defined benefit plans	26.18	72.97	72.97	**291.90**
Tax related to items that will not be reclassified to profit or loss	6.59	18.37	18.37	**73.46**
Total Other Comprehensive (loss)/Income(XVII)	**32.77**	**91.34**	**91.34**	**365.36**
Total Comprehensive (loss)/Income(XVI+XVII)	**782.27**	**581.79**	**670.07**	**2,305.22**
XVIII. Earnings per equity share:				
(1) Basic	3.07	2.01	2.37	7.93
(2) Diluted	2.59	1.95	2.30	7.72

First-time Adoption of Ind AS

The Company has adopted **Indian Accounting Standards (Ind AS)** with effect from **1 April 2026**. Accordingly, **1 April 2025** has been considered as the date of transition to Ind AS and an opening Ind AS Balance Sheet has been prepared as at that date in accordance with **Ind AS 101 – First-time Adoption of Indian Accounting Standards**.

These financial results for the **quarter ended 30 June 2026** are the first quarterly financial statements of the Company prepared in accordance with Ind AS. The corresponding comparative information for the quarter ended **30 June 2025** has been restated/recast, wherever applicable, to comply with the requirements of Ind AS.

The transition from previous GAAP to Ind AS has resulted in adjustments primarily relating to **leases, financial instruments, employee benefits, deferred tax and other applicable Ind AS requirements**. The impact of such

transition adjustments on the opening equity as at **1 April 2025**, equity as at **31 March 2026**, and the financial performance for the relevant comparative periods has been determined in accordance with Ind AS 101.

Following reconciliations of equity and total comprehensive income between previous GAAP and Ind AS, along with explanations of material adjustments arising from the transition.

Statement of Changes in Equity and Statement of Impact of Transition to Ind AS on Profit and Other Comprehensive Income

Year Ended 31st March 2026					
Adjustment Category	**Amount**	**Change In Profit & OCI**			
		Expense	**Income**	**OCI**	**Total**
Equity / Retained Earnings As Per Indian GAAP as on 01/04/2025	4,258.05	**-**	**-**	**-**	
Ind AS 19_Gratuity (Defined Benefit Obligation)	-	285.11	-	285.11	**-**
Ind AS 116_Rent Building — ROU Asset & Lease Liability	-226.82	297.65	-	-	**-297.65**
Ind AS 109_Term Loans — EIR (Amortised Cost)	29.53	-	10.06	-	**10.06**
Ind AS 109_Security Deposits — Given (Assets)	-6.90	6.88	-	-	**-6.88**
Ind AS 109_Security Deposits — Received (Liabilities)	0.27	-	0.27	-	**0.27**
Ind AS 12_Deferred Tax on Above Adjustments	-51.32	217.56	-	71.76	**-145.80**
Total	**4,002.80**	**807.21**	**10.33**	**356.87**	**-440.01**

Quarter Ended 30th June 2026					
Adjustment Category	**Amount**	**Change In Profit & OCI**			
		Expense	**Income**	**OCI**	**Total**
Equity / Retained Earnings As Per Indian GAAP as on 01/04/2025	-	-	-	-	**-**
Ind AS 19_Gratuity (Defined Benefit Obligation)	-	18.73	-	22.72	**3.99**
Ind AS 116_Rent Building — ROU Asset & Lease Liability	-	105.09	-	-	**-105.09**
Ind AS 109_Term Loans — EIR (Amortised Cost)	-	3.49	20.79	-	**17.29**
Ind AS 109_Security Deposits — Given (Assets)	-	1.62	0.03	-	**-1.59**
Ind AS 109_Security Deposits — Received (Liabilities)	-	0.07	0.07	-	**-0.00**
Ind AS 12_Deferred Tax on Above Adjustments	-	32.93	-	5.72	**-27.21**
Total	**-**	**161.93**	**20.89**	**28.44**	**-112.61**

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322

MSNT & ASSOCIATE LLP 018542C/C400322 CHARTERED ACCOUNTANTS

Navodit tyagi
Partner
Membership no. :- 533375
UDIN no. :- 26533375LJICNF2743
Place :- Noida
Date :- 14th August 2026

For & on behalf of the board of directors
CHANDAN HEALTHCARE LIMITED

Amar singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 14th August 2026

Asmita singh
Managing director
Din. :- 01098055
Place :- Lucknow
Date :- 14th August 2026

Rajeev Nain
CFO & Company secretary
Place :- Lucknow
Date :- 14th August 2026

MSNT & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

14th Aug, 2026.

To,
The Manager – Listing Department.
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Reference: - Chandan Healthcare Limited

NSE Code:-CHANDAN

ISIN: INE0B2N01016

Sub: Statement of Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations) for the Quarter ended on 30th June, 2026.

Dear Sir,

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meeting held on Wednesday, 12 Aug, 2026.

This is for your information and records please.

Please take the above information on record.

Thanking You,

Yours Faithfully

: **Head Office:** - A-40, I-Thum, Tower-B,10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.
: **CA Saurabh Tyagi:** 7718802884, **CA Navodit Tyagi:** 9167436404, **CA Manoj Modi:** 9022059201.
: saurabh@msnt.in navodit@msnt.in manoj@msnt.in

Annexure 1-Statement of Deviation or Variation in Utilization of Funds Raised

Name of the Listed Entity	Chandan Healthcare Limited
Mode of Raising Fund	Initial Public Offer
Date of raising Fund	17th Feb, 2025
Amount Raised (Rs. in Lakhs)	7044.64
Report filed for the quarter/half year	30th June , 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	--
If yes, Date of shareholder approval	--
Explanation for Deviation/Variation	--
Comments of the Audit Committee after review	
Comments of the Auditors, if any	

Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	Original Allocation (Amount in Lakhs)	Modified Allocation, if any	Funds Utilised till 30.06.2026	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
				(Amount in Lakhs)		
Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ashiyana, Lucknow, Uttar Pradesh.						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and fabrication work	NO	710.11	0	710.11	0	
Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ayodhya , Uttar Pradesh.						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and fabrication	NO	710.23	0	710.23	0	

work						
Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Jankipuram , Lucknow, Uttar Pradesh.						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required civil, electric and fabrication work	NO	3281.58	0	2764.55	0	Partially Utilised till June, 2026
General corporate purposes	NO	1672.45	0	1672.45	0	
Issue related expenses	NO	670.27	0	670.27	0	

Deviation or variation could mean:

Deviation in the Objects or purposes for which the funds have been raised or
Deviation in the amount of funds actually utilized as against what was originally disclosed or
Change in terms of a contract referred to in the funds raising documents I.e., prospectus, Letter of Offer

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322

Navodit Tyagi
Partner
Membership No.-533375
UDIN No: 26533375YLXGCR6685
Place: Noida
Date: 14.08.2026

To
The Board of Directors,
Chandan Healthcare Limited
Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram,
Lucknow, Uttar Pradesh – 226021

Statutory Auditor's Certificate certifying utilization of the Net offer proceeds received consequent to the issue of equity warrants through the Preferential issue (PI)during the quarter ended 30th June, 2026.

1. This certificate is issued in accordance with the terms of our engagement letter <dated>

2. We, MSNT & Associates LLP, Chartered Accountants (Firms' Registration No:018542C/C400322), the statutory auditors of ("the Company"), having its registered office at Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021 have examined the unaudited books of account for the period 1st April 2026 to 30th June 2026 to certify if the utilization of the Net offer proceeds received through the PI for the quarter ended 30th June (included in "Annexure A") is in agreement with the unaudited books of account and in accordance with the terms of utilization included in the Notice of EGM to the PI.

Management's Responsibility for the Statement

3. Management of the Company is responsible for the appropriate utilization of funds for objects stated in the Letter of offer of the Company.

4. The Management of the Company is also responsible for the adherence to the provisions of the Companies Act, 2013 and all the applicable guidelines/ regulations specified by the Securities and Exchange Board of India ("SEBI"), the Ministry of Corporate Affairs ("MCA").

Auditor's Responsibility

5. Our responsibility is to provide limited assurance on whether the payments made representing the utilization of the Net proceeds of the PI is in agreement with the unaudited books of account and in accordance with the purposes mentioned in the Notice of EGM to the PI. Nothing contained in this Certificate, nor anything said or done in the course of, or in connection with the services that are subject to this Certificate, will extend to any duty of care that we may have in our capacity of the statutory auditors of any financial statements of the Company.

6. We have conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the Institute of Chartered Accountants of India ("ICAI") and Standards on Auditing specified under Section 143(10) of the Companies Act, 2013. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by ICAI. The procedures performed vary in nature and timing from, and are less extent than for, a reasonable assurance.

Consequently, the level of assurance obtained is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

7. We have neither performed an audit nor a review in accordance with the generally accepted auditing standards in India and accordingly we do not express any opinion on the contents of the Statement. Had we performed additional procedures in accordance with the generally accepted standards on auditing in India, other matters might have come to our attention that would have been reported.

8. Accordingly, we have performed the following procedures in relation to the Statement:

   a) Obtained and read the "Statement" for the period from 1^{st} April 2026 to 30^{th} June 2026.
   b) Traced the "Amount as proposed in the Offer Document" from the Notice of EGM dated 14^{th}October, 2025
   c) Traced the Initial Public Offer/ Qualified Institutional Placement/Preferential Issue/Right Issue (as applicable) proceeds from the bank statement.
   d) Verified the utilization with the supporting documents and other records including the entries in the unaudited books of account of the Company for the period from 1^{st} April 2026 to 30^{th} June 2026.
   e) Verified the closing balances in Current Bank Account and Fixed Deposit Accounts (as mentioned in the statement) from the bank confirmation provided by the management.
   f) Made necessary inquiries with the management and obtained relevant representations in respect of matters relating to the Statement.

9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements as issued by ICAI.

Conclusion

10. Based on our examination, as referred above, and the information and explanations provided to us by the Management of the Company, nothing has come to our attention that causes us to believe that the utilization of the Net proceeds during the period 1^{st} April 2026 to 30^{th} June 2026 arising from the Company's PI (as applicable), read with and subject to the notes thereon (included in "Annexure A"), are not in agreement with the unaudited books of account of the Company or have not been used for the purposes as mentioned in the Notice of EGM of offer to the PI.

Restriction on Use

11. This certificate is issued based on the request from the Management of the Company for the onward submission to monitoring agency in connection with the utilization of the proceeds from Preferential Issue under the Issue of Capital and Disclosure Requirements Regulations and should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For M/s. MSNT & Associates
Chartered Accountants
FRN No.: 018542C/C400322

MSNT & ASSOCIATE LLP
018542C/C400322
CHARTERED ACCOUNTANTS

Navodit Tyagi
Membership No.: 533375
Place: Noida
Date: 12.08.2026
UDIN: **26533375QJBEXW1779**

"Annexure A"

Name of the issuer:

For quarter ended: 30th June,2026

(a) Deviation from the objects: N/A

(b) Range of Deviation: N/A

Declaration:

We declare that this report provides a true and fair view of the utilization of the issue proceeds.

We declare that we do not have any direct/indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship/interest while reporting the utilization of the issue proceeds by the issuer.

Signature:

Rajeev Kumar Nain
(CFO and Company Secretary)
Chandan Healthcare Limited

1) **Issuer Details:**
Name of the issuer: Chandan Healthcare Limited
Names of the promoter:
Industry/Sector to which it belongs: Healthcare

2) **Issue Details:**
Issue period: 1st April 2026 to 30th June 2026
Type of issue (public/rights): Preferential Issue
Type of specified securities: Share Warrants
IPO Grading, if any: N/A
Issue size (in crore/million): 104.13 Crores

3) **Details of the arrangement made to ensure the monitoring of issue proceeds:**

Particulars	Reply (Yes/No/ NA)	Comments of the chartered accountant
Whether all utilization is as per the disclosures in the Offer Document?	Yes	
Whether shareholder approval has been obtained in case of material deviations from expenditures disclosed in the Offer Document?	N/A	
Whether the means of finance for the disclosed objects of the issue has changed?	No	
Is there any major deviation observed over the earlier monitoring agency reports?	N/A	
Whether all Government/statutory approvals related to the object(s) have been obtained?	N/A	
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Yes	
Are there any favorable events improving the viability of these object(s)?	N/A	
Are there any unfavorable events affecting the viability of the object(s)?	N/A	
Is there any other relevant information that may materially affect the decision making of the investors?	No	

4) Details of object(s)s to be monitored:

(i) **Cost of object(s)-**

S. No.	Item Head	Original- cost as per offer document (Rs.)	Revised Cost (Rs.)	Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1	Business Expansion	44,50,00,000	NA			
2	Acquisitions	50,00,00,000	NA			
3	GCP	9,63,00,000	NA			
	Total	1,04,13,00,000				

Note: Necessary explanation to be added, wherever applicable
*Business expansion activities also include settlement of outstanding dues payable to various vendors.

(ii) **Progress in the object(s) –**

Object(S)	Amount as per final offer document	Amount utilised at the beginning of the reported quarter	Amount utilised during the reported quarter	Amount utilised at the end of the reported quarter	Total unutilized amount as at the end of the reported quarter	Reason for idle funds	Proposed course of actions
Business Expansion	44,50,00,000	12,17,53,881	11,19,99,937	23,37,53,818	5,79,92,182		Amount is invested in Fixed Deposits and remaining is held as bank balance in preferential issue account Refer Note 1 & 2
Acquisitions	50,00,00,000	0	0	0	0		Refer Note 1
GCP	9,63,00,000	4,75,54,000	0	4,75,54,000	0		Refer Note 1
Total	1,04,13,00,000	16,93,07,881	11,19,99,937	28,13,07,818	5,79,92,182		

Note: Note 1: During the reported quarter ended June 30, 2026, the utilised proceeds of Rs. 11,19,99,937, was transferred to current accounts of the Company for utilisation towards Object 1: Business Expansion for operational ease. The transferred proceeds were fully utilized as at end of the reported quarter.
Note 2: Out of issue proceeds of Rs 1,04,13,00,000, the Company is yet to receive Rs. 70,20,00,000 and shall be payable by the warrant holders upon conversion of warrants into equity shares within 18 months from the date of allotment of the share warrants, i.e. by July 28, 2027, as per notice to shareholders.

(iii) Deployment of unutilized Preferential issue (PI) proceeds:

S. No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning (as at quarter end)	Return on Investment (%)	Market value as at the end of quarter (if the market value is not feasible, provide NAV/NRV/Book value of the same)
1	Fixed Deposits	1,36,119		-	6.5% P.a	1,36,119
2	Bank Balance in preferential issue account with ICICI Bank	5,78,56,063	-	2,22,422	-	5,80,78,485
	Total	5,79,92,182		2,22,422		5,82,14,604

Note: Interest include Rs 2,22,422

(iv) Delay in implementation of the objects:

Object(s)	Completion Date		Delay (no. of days/ months)	Comments of the chartered accountant	
	As per the Offer Document	Actual		Reason of delay	Proposed course of action
		Not Applicable			

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

S. No.	Item heads	Amount (Rs.)	Comments of the chartered accountant
		Nil	